| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.RES.73.6.1061 |
| P698 | PubMed publication ID | 8222078 |
| P50 | author | Bernard Fermini | Q67656054 |
| P2093 | author name string | Z Wang | |
| S Nattel | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1061-1076 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents | |
| P478 | volume | 73 |
| Q73112803 | 4-aminopyridine activates potassium currents by activation of a muscarinic receptor in feline atrial myocytes |
| Q49824348 | A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy |
| Q73947744 | A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle |
| Q74625243 | Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes |
| Q42777572 | Advances in the Pharmacologic Management of Atrial Fibrillation |
| Q34383573 | Advances in the Pharmacological Treatment of Atrial Fibrillation |
| Q61965157 | Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+channels |
| Q42700209 | An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes |
| Q90685517 | Anti-arrhythmic properties of non-antiarrhythmic medications |
| Q53943964 | Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. |
| Q45115473 | Atrial electrical remodeling by rapid pacing in the isolated rabbit heart: effects of Ca++ and K+ channel blockade |
| Q38111636 | Atrial selectivity of antiarrhythmic drugs |
| Q39785206 | Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. |
| Q39760319 | Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. |
| Q36013079 | Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity |
| Q34765700 | Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation |
| Q41095531 | Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels |
| Q36488693 | Blockade of Kv1.5 by paroxetine, an antidepressant drug |
| Q36627616 | Blockade of Kv1.5 channels by the antidepressant drug sertraline |
| Q41880477 | Can inhibition of IKur promote atrial fibrillation? |
| Q38854252 | Cardiac Delayed Rectifier Potassium Channels in Health and Disease |
| Q48293093 | Cardiac Potassium Channels: Physiological Insights for Targeted Therapy. |
| Q60721487 | Cardiac ion channels |
| Q41639367 | Cardiac potassium currents and channels--part I: basic science aspects |
| Q26751133 | Cardiovascular Action of Insulin in Health and Disease: Endothelial L-Arginine Transport and Cardiac Voltage-Dependent Potassium Channels |
| Q42880713 | Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials |
| Q73020175 | Characterization of a beta-adrenergically inhibited K+ current in rat cardiac ventricular cells |
| Q37418226 | Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. |
| Q24563816 | Characterization of a voltage-gated K+ channel beta subunit expressed in human heart |
| Q71806031 | Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization |
| Q44796320 | Clarithromycin reduces Isus and Ito currents in human atrial myocytes with minor repercussions on action potential duration |
| Q42549033 | Comparative effects of nonsedating histamine H1 receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels |
| Q92938650 | Computational Study of the Loss-of-Function Mutations in the Kv1.5 Channel Associated with Atrial Fibrillation |
| Q45258600 | Cross-talk between beta(1)-adrenoceptors and ET(A) receptors in modulation of the slow component of delayed rectifier K(+) currents |
| Q89170102 | Deep phenotyping of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes |
| Q27348745 | Detailed Anatomical and Electrophysiological Models of Human Atria and Torso for the Simulation of Atrial Activation |
| Q73020161 | Differences between outward currents of human atrial and subepicardial ventricular myocytes |
| Q48587407 | Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure |
| Q37789112 | Differential gene expressions in atrial and ventricular myocytes: insights into the road of applying embryonic stem cell-derived cardiomyocytes for future therapies |
| Q36303805 | Drug therapy for atrial fibrillation: where do we go from here? |
| Q44278214 | Effect of androgen deficiency on mouse ventricular repolarization |
| Q41066848 | Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5. |
| Q37614642 | Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation |
| Q44533629 | Effects of U50,488H on transient outward and ultra-rapid delayed rectifier K+ currents in young human atrial myocytes |
| Q51759464 | Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. |
| Q43261549 | Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes |
| Q42616386 | Effects of human atrial ionic remodelling by β-blocker therapy on mechanisms of atrial fibrillation: a computer simulation |
| Q42928203 | Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5 |
| Q28369361 | Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels |
| Q41937994 | Effects of propafenone on K currents in human atrial myocytes |
| Q42198666 | Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels |
| Q33206302 | Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. |
| Q44367464 | Effects of the chromanol HMR 1556 on potassium currents in atrial myocytes |
| Q52319407 | Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes. |
| Q44024309 | Electrophysiologic cardiac effects of the new local anesthetic IQB-9302 and of bupivacaine in the anesthetised dog. |
| Q40330250 | Electrophysiological characterization of three non-synonymous single nucleotide polymorphisms (R87Q, A251T, and P307S) found in hKv1.5. |
| Q34066888 | Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking |
| Q37286117 | Empirical correlation of triggered activity and spatial and temporal re-entrant substrates with arrhythmogenicity in a murine model for Jervell and Lange-Nielsen syndrome |
| Q34168352 | Evidence for multiple open and inactivated states of the hKv1.5 delayed rectifier |
| Q33777244 | Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions |
| Q52673971 | Factors affecting basket catheter detection of real and phantom rotors in the atria: A computational study. |
| Q34066987 | Four and a half LIM protein 1C (FHL1C): a binding partner for voltage-gated potassium channel K(v1.5). |
| Q47558785 | From ionic to cellular variability in human atrial myocytes: an integrative computational and experimental study |
| Q34068844 | Functional Characterization of Human Stem Cell-Derived Cardiomyocytes |
| Q24306905 | Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation |
| Q48367671 | Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase. |
| Q33710653 | Hormonal control of cardiac ion channels and transporters |
| Q38790685 | How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? |
| Q42385429 | How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? |
| Q40616801 | Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line |
| Q40969037 | Identification, cloning and expression of rabbit vascular smooth muscle Kv1.5 and comparison with native delayed rectifier K+ current |
| Q36248808 | Impact of ancillary subunits on ventricular repolarization |
| Q33813481 | Impact of sarcoplasmic reticulum calcium release on calcium dynamics and action potential morphology in human atrial myocytes: a computational study |
| Q35129668 | Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment |
| Q37230979 | Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel |
| Q43800920 | Inhibitory effect of bepridil on hKv1.5 channel current: comparison with amiodarone and E-4031. |
| Q36670460 | Innovative approaches to anti-arrhythmic drug therapy. |
| Q35231876 | Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation |
| Q37833065 | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation |
| Q47580184 | Ion Channel Trafficking: Control of Ion Channel Density as a Target for Arrhythmias? |
| Q26829681 | Ion Channels in the Heart |
| Q34101658 | Ion channel trafficking: a new therapeutic horizon for atrial fibrillation |
| Q40834298 | Is there a future for antiarrhythmic drug therapy? |
| Q48605283 | Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII. |
| Q33960965 | K(+) channels as therapeutic drug targets |
| Q37406359 | K+ current changes account for the rate dependence of the action potential in the human atrial myocyte |
| Q36064577 | KCNE Regulation of K(+) Channel Trafficking - a Sisyphean Task? |
| Q48007771 | Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? |
| Q24313536 | KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias |
| Q42633034 | Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model |
| Q24318903 | Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue |
| Q35974594 | Long QT and ventricular arrhythmias in transgenic mice expressing the N terminus and first transmembrane segment of a voltage-gated potassium channel |
| Q28482100 | Markov models of use-dependence and reverse use-dependence during the mouse cardiac action potential |
| Q33892635 | Mathematical models of canine right and left atria cardiomyocytes |
| Q89982580 | Mechanical stretch increases Kv1.5 current through an interaction between the S1-S2 linker and N-terminus of the channel |
| Q42713019 | Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers |
| Q60183578 | Mechanisms and Drug Development in Atrial Fibrillation |
| Q41219769 | Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. |
| Q42513131 | Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes |
| Q37807195 | MicroRNAs and atrial fibrillation: new fundamentals |
| Q26779602 | Modeling Electrophysiological Coupling and Fusion between Human Mesenchymal Stem Cells and Cardiomyocytes |
| Q39639701 | Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1 |
| Q46836414 | Modulation of the atrial specific Kv1.5 channel by the n-3 polyunsaturated fatty acid, alpha-linolenic acid |
| Q38854244 | Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology |
| Q44631900 | Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels |
| Q33931559 | Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium |
| Q77760405 | Molecular correlates of the calcium-independent, depolarization-activated K+ currents in rat atrial myocytes |
| Q28539142 | New aspects of HERG K⁺ channel function depending upon cardiac spatial heterogeneity |
| Q34503407 | New ideas about atrial fibrillation 50 years on. |
| Q40962992 | Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2. |
| Q24311926 | Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation |
| Q35489060 | Novel pharmacological targets for the rhythm control management of atrial fibrillation. |
| Q33557233 | Open channel block of Kv1.5 currents by citalopram |
| Q36436304 | Opening and closing of KCNKO potassium leak channels is tightly regulated |
| Q77400619 | Overexpression of nerve growth factor in the heart alters ion channel activity and beta-adrenergic signalling in an adult transgenic mouse |
| Q36124154 | PKC and AMPK regulation of Kv1.5 potassium channels |
| Q41661139 | Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp |
| Q36842497 | Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation |
| Q43710067 | Pergolide block of the cloned Kv1.5 potassium channels |
| Q35647167 | Pharmacogenomics of cardiovascular complications in diabetes and obesity |
| Q37781356 | Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy |
| Q85174031 | Pharmacology of Cardiac Potassium Channels |
| Q34701024 | Potassium channels: gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. |
| Q43920140 | Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics |
| Q28205333 | Potassium leak channels and the KCNK family of two-P-domain subunits |
| Q28379324 | Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature |
| Q47849876 | Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance |
| Q43188989 | Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine |
| Q35897567 | Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol |
| Q51354497 | Regulation of human cardiac Kv1.5 channels by extracellular acidification. |
| Q31997375 | Regulation of voltage-gated K+ channel expression in the developing mammalian myocardium |
| Q42694191 | Revealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity. |
| Q46274903 | Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure |
| Q42766370 | Serum positive for the autoantibody against the β(1)-adrenoceptor from Chinese patients with congestive heart failure decreases I(ss) in mouse cardiac myocytes |
| Q34361080 | Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart |
| Q37594973 | Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias |
| Q40404466 | Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels |
| Q34046966 | Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers |
| Q28346372 | Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5) |
| Q57697033 | Structure-Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of Kv1.5 Channel Blockers |
| Q51137597 | Sumo Modification of Ion Channels. |
| Q37005224 | TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes |
| Q28286212 | Targeted deletion of kcne2 impairs ventricular repolarization via disruption of I(K,slow1) and I(to,f) |
| Q57022048 | The N terminus and transmembrane segment S1 of Kv1.5 can coassemble with the rest of the channel independently of the S1-S2 linkage |
| Q35026648 | The antiarrhythmic agent bertosamil induces inactivation of the sustained outward K+ current in human atrial myocytes. |
| Q44854332 | The comparative hemodynamic effects of intravenous IQB-9302 and bupivacaine in anesthetized rats |
| Q36144683 | The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization |
| Q38643358 | The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation |
| Q37166906 | The role of the renin-angiotensin system blocking in the management of atrial fibrillation |
| Q35041683 | The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes |
| Q40395459 | The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. |
| Q36522100 | There and back again: Iterating between population-based modeling and experiments reveals surprising regulation of calcium transients in rat cardiac myocytes. |
| Q56638322 | Toxikologie der Lokalan�sthetika |
| Q84459461 | Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes |
| Q98771654 | Ultrarapid Delayed Rectifier K+ Channelopathies in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes |
| Q34509672 | Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. |
| Q24653858 | Voltage-dependent inactivation of the human K+ channel KvLQT1 is eliminated by association with minimal K+ channel (minK) subunits |
| Q37464784 | Voltage-gated potassium channels as therapeutic targets |
| Q50690847 | [New developments in the antiarrhythmic therapy of atrial fibrillation]. |
Search more.